103028-81-5

Basic information

• Product Name: 6-METHOXY-1-INDANAMINE
• Synonyms: 6-METHOXY-INDAN-1-YLAMINE;6-METHOXY-1-INDANAMINE;1-AMINO-6-METHOXY INDAN;6-Methoxy-2,3-dihydro-1H-inden-1-aMine;2,3-Dihydro-6-methoxy-1H-inden-1-amine;6-Methoxyindan-1-amine;1H-Inden-1-amine,2,3-dihydro-6-methoxy
• CAS NO: 103028-81-5
• Molecular Formula: C₁₀H₁₃NO
• Molecular Weight: 163.22
• EINECS: 604-604-1
• Mol File: 103028-81-5.mol

Chemical Properties

• Boiling Point: 266℃
• Flash Point: 119℃
• Appearance: /
• Density: 1.087
• Vapor Pressure: 0.009mmHg at 25°C
• Refractive Index: 1.562
• PKA: 9.18±0.20(Predicted)
• CAS DataBase Reference: 6-METHOXY-1-INDANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHOXY-1-INDANAMINE(103028-81-5)
• EPA Substance Registry System: 6-METHOXY-1-INDANAMINE(103028-81-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 103028-81-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
6-Methoxy-1-indanamine is used as a research compound for its potential applications in the treatment of psychiatric disorders. Its ability to modulate serotonin levels and inhibit monoamine oxidase makes it a candidate for further investigation into its therapeutic effects.
Used in Forensic Toxicology:
In the field of forensic toxicology, 6-Methoxy-1-indanamine is used as a marker for the identification and analysis of impurities in illegal drug preparations. Its presence can provide valuable information about the manufacturing process and the potential risks associated with the consumption of these substances.
Used in Drug Enforcement:
6-Methoxy-1-indanamine is utilized by drug enforcement agencies as a substance of concern. Its identification in illegal drug preparations can aid in the detection and prevention of drug-related crimes, as well as in the development of strategies to combat the distribution and use of illicit substances.

InChI:InChI=1/C10H13NO/c1-12-8-4-2-7-3-5-10(11)9(7)6-8/h2,4,6,10H,3,5,11H2,1H3

Upstream product

• 180915-76-8 6-methoxyindan-1-one oxime 
• 64-19-7 acetic acid 
• 3469-07-6 5-methoxy-1H-indene 
• 13623-25-1 6-methoxy-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 133497-57-1 1-amino-6-hydroxyindan 

Relevant articles and documents

Synthesis and Reactivity of 6- and 7-Methoxyindanoaziridines

The synthesis,spectral, and reactivity properties of 6-methoxy- and 7-methoxyindanoaziridines (8 and 9,respectively) are detailed.Hydrolysis of each aziridine produced the corresponding trans and cis-2-amino-1-indanols in approximately 1:2 ratio, respectively.The 7-methoxy adduct 9 underwent hydrolysis approximately 250 times faster then the isomeric 6-methoxyaziridine 8 at pH 8.88.Both the product profiles and the kinetic rate data for the hydrolysis of 8 and 9 are consistent with a mechanism in which protonation of the aziridine precedes the rate-determining ring-opening step to generate the corresponding benzylic cation.The products generated in these reactions paralleled those reported for the hydrolysis of the antineoplastic agent mitomycin C under reductive conditions.The implications of these findings in relation to the mode of action of mitomycin C are discussed.

Hydroxy-1-aminoindans and derivatives: Preparation, stability, and reactivity

The chemical stability and reactivity of hydroxy-1-aminoindans and their N-propargyl derivatives are strongly affected by the position of the OH group and its orientation relative to that of the amino moiety. Thus, the 4- and 6-OH regioisomers were found to be stable, while the 5-OH analogues were found to be inherently unstable as the free bases. The latter, having a para orientation between the OH and the amino moieties, could be isolated only as their hydrochloride salts. 7-Hydroxy-1-aminoindans and 7-hydroxy-1- propargylaminoindans represent an intermediate case; while sufficiently stable even as free bases, they exhibit, under certain experimental conditions, unexpected reactivity. The instability of the 5- and 7-hydroxy-aminoindans is attributed to their facile conversion to the corresponding, reactive quinone methide (QM) intermediates. The o-QM obtained from 7-hydroxy-aminoindans was successfully trapped with ethyl vinyl ether via a Diels-Alder reaction to give tricyclic acetals 32a,b.

Deconstructive Oxygenation of Unstrained Cycloalkanamines

A deconstructive oxygenation of unstrained primary cycloalkanamines has been developed for the first time using an auto-oxidative aromatization promoted C(sp3)?C(sp3) bond cleavage strategy. This metal-free method involves the substitution reaction of cycloalkanamines with hydrazonyl chlorides and subsequent auto-oxidative annulation to in situ generate pre-aromatics, followed by N-radical-promoted ring-opening and further oxygenation by 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO) and m-cholorperoxybenzoic acid (mCPBA). Consequently, a series of 1,2,4-triazole-containing acyclic carbonyl compounds were efficiently produced. This protocol features a one-pot operation, mild reaction conditions, high regioselectivity and ring-opening efficiency, broad substrate scope, and is compatible with alkaloids, osamines, and peptides, as well as steroids.

SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS

Therapeutic compounds, and methods, compositions, and medicaments related thereto are disclosed herein.

Process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates

A process for preparing indanylamine and aminotetralin derivatives from indanone or tetralone oximes by acylating the oximes with an organic anhydride, followed by catalytic hydrogenation in the presence of an organic anhydride with subsequent hydrolysis is described. The process is commercially feasible providing indanylamine and aminotetralin derivatives in high yield that are useful as intermediates in the production of therapeutically active compounds. Also described are novel intermediates, 1-indanone O-acetyl oximes and 1-tetralone O-acetyl oximes.

Substituted aryl 1,4-pyrazine derivatives

Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.